Actively Recruiting
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Led by University Hospital, Alexandroupolis · Updated on 2025-04-24
60
Participants Needed
2
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function has not been investigated yet. Taking into account that Ang-2 has destructive effect on kidneys, the investigation of the effect of its inhibition in diabetic patients who have already renal function deterioration may provide a valuable information in scientific community.
CONDITIONS
Official Title
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with diabetes
- Patients with diabetic macular edema, neovascular age related macular degeneration, or macular edema secondary to retinal vein occlusion
- Patients already receiving nephroprotective drugs
You will not qualify if you...
- Patients with end stage renal disease
- Pregnancy
- Patients with other retinal disorders
- Previous renal transplantation
- Patients under hemodialysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University Hospital of Alexandroupolis
Alexandroupoli, Evros, Greece, 68100
Actively Recruiting
2
University Hospital of Alexandroupolis
Alexandroupoli, Greece, 68100
Completed
Research Team
A
Asli Perente, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here